Barcelona, Spain

Mari/ A Prat Quin

This inventor holds 1 USPTO granted patent. Top assignee: Prodesfarma, S.a.. Active years: 1996.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1996

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Mari A Prat Quin

Introduction

Mari A Prat Quin is a notable inventor based in Barcelona, Spain. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for treating cardiovascular conditions. His work exemplifies the intersection of chemistry and medicine, showcasing the potential of innovative solutions in healthcare.

Latest Patents

Mari A Prat Quin holds a patent for "1-aryloxy-3-alkylamino-2-propanol-nitrate esters, the use thereof." This patent includes the general formula for the compounds he developed, which are designed to treat cardiovascular affections. The compounds consist of various structural elements, including a chain of specific formulas and functional groups that enhance their therapeutic efficacy.

Career Highlights

Throughout his career, Mari A Prat Quin has been associated with Prodesfarma, S.A., where he has contributed to the advancement of pharmaceutical research. His innovative approach to drug development has led to the creation of valuable therapeutic agents that address critical health issues.

Collaborations

Some of his notable coworkers include Joan Pi Sallent and Dagmar Vedrilla Veit. Their collaborative efforts have further enriched the research environment at Prodesfarma, fostering a culture of innovation and excellence.

Conclusion

Mari A Prat Quin's work in the field of pharmaceuticals highlights the importance of innovation in developing effective treatments for cardiovascular diseases. His contributions continue to impact the healthcare industry positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…